


Effect of **hyperthermic intraperitoneal chemotherapy** on patients with advanced colorectal cancer: a systematic review and meta-analysis

Hyperthermic intraperitoneal chemotherapy (HIPEC)



Advanced colorectal cancer (CRC)

10 high-quality cohort studies
4 randomized controlled trial
n=2,851 patients

 The aim is to comprehensively evaluate the standalone effect of HIPEC in advanced CRC.

1. In terms of survival

HIPEC significantly improved

1-year DFS OR =1.64, 95%CI: 1.09-2.46

5-year OS OR=1.49, 95%CI: 1.10-2.03

2. Regarding recurrence

• Peritoneal metastasis (PM) and recurrence

HIPEC significantly reduced the overall PM rate

OR=0.66, 95%CI: 0.49-0.90

OR=0.13, 95%CI: 0.03-0.63

Therapeutic HIPEC

Reduced peritoneal recurrence for previous PM

OR=0.71, 95%CI: 0.52-0.97

Preventive HIPEC

Reduced PM rate without previous PM

• No significant effect of HIPEC on overall recurrence rate

3. In complications

Neutropenia OR=3.21, 95%CI: 1.74-5.90

Thrombopenia OR=5.77, 95%CI: 1.65-20.09

Conclusion



The use of HIPEC in the treatment of advanced CRC may result in improved survival rates and a reduction in peritoneal recurrence, but complications should be noted.



In patients with advanced CRC who have not developed PM, the use of HIPEC may serve to prevent PM.